Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

Also called NCT03256838

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03256838
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03256838. Allocation not applicable; no masking; primary purpose other. Start 2017-04-12 (actual); primary completion 2018-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
Condition
Kidney Failure, Chronic
Condition
End-stage Renal Disease
Condition
Phosphorus Metabolism Disorders
Condition
Hyperphosphatemia
Intervention (Drug)
Ferric Citrate
Lead sponsor
Panion & BF Biotech Inc. (class: industry)

Record details

Record id
cardio:ct-nct03256838
Content hash
261286e94a2e16901df85e4676008bfc8f12dadb1aa1faba683d4319a63201da